Intravenous gamma globulin in progressive MS

S. D. Cook, R. Troiano, C. Rohowsky‐Kochan, A. Jotkowitz, L. Bielory, P. D. Mehta, J. Oleske, S. Bansil, P. C. Dowling

Research output: Contribution to journalArticlepeer-review

41 Scopus citations


In an attempt to prevent disease exacerbations, intravenous gamma globulin (500 mg to 2 g/kg) plus methylprednisolone was administered monthly to 14 patients with progressive multiple sclerosis, 11 of whom were steroid dependent. Seventeen exacerbations of disease activity were seen in 11 patients over a mean follow‐up period of 7.8 months. Four exacerbations occurred in 3 patients within one month of receiving 1.6 to 2.0 g/kg of intravenous gamma globulin (IVGG). Most exacerbations occurred within 2 weeks of steroids being tapered; thus a steroid sparing effect of IVGG could not be demonstrated. We conclude that IVGG plus methylprednisolone can be given safely at monthly intervals for a prolonged period but in the dosage administered did not prevent exacerbations in 80% of patients with progressive multiple sclerosis. 1992 Blackwell Munksgaard

Original languageEnglish (US)
Pages (from-to)171-175
Number of pages5
JournalActa Neurologica Scandinavica
Issue number2
StatePublished - Aug 1992

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Intravenous gamma globulin in progressive MS'. Together they form a unique fingerprint.

Cite this